E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084382 |
E.1.2 | Term | Coronavirus disease 2019 |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Rate, in percent, of subjects in each investigation arm displaying a SARS-CoV-2 RT-PCR Ct count above 34 (>34 cycles) performed on a saliva sample collected at Day 6 of experiment, after full treatment completion. |
|
E.2.2 | Secondary objectives of the trial |
1)Clinical evolution based on the daily filling of the FLU-PRO self-questionnaire (daily comparison of the distribution and mean of FLU-PRO score in each investigation arm)
2)Rate of subjects in each investigation arm displaying a negative viral culture of a nasopharyngeal swab sample collected at Day 3 of experiment
3)Median time, in days, of viral shedding in the subjects in each investigation arm (time of viral shedding=nb of days in experiment of a saliva sample which RT-PCR Ct count is >34)
4)Evolution of the daily distribution and mean RT-PCR Ct count compared between the two investigation arms, performed on saliva samples collected daily in all the subjects, from Day 1 to Day 6
5)Rate of subjects in each investigation arm having reported any kind of adverse events and reactions including specific comparison according to :
- the organic system they affect, be it encompassed by the table in Appendix 2 or not ;
- their quality and severity class : AE, SAE, SUSAR
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Provided informed consent following an exhaustive and fully-understood information
- Aged ≥16 years and ≤65 years
- Does not present any criteria of redirection towards the Emergency Room or towards a direct hospitalization
- Time from symptom onset (TFSO) ≤48 hours AND tested positive at the Rapid Antigenic Test
|
|
E.4 | Principal exclusion criteria |
- Pregnancy, breastfeeding, or any woman of child-bearing potential that does not benefit from any proper contraception and whose Last Menstrual Period occurred 20 days ago or more (≥ 20 days).
- Immunosuppression, whatever the type, including drug-induced cases.
- COVID-19 requiring hospitalization or redirection towards the Emergency Room.
- Anti-COVID-19 vaccination, whatever the vaccine, as soon as first dose has been administered.
- Former COVID-19 infection diagnosed upon positive SARS-CoV-2 RT-PCR test results.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Rate, in percent, of subjects in each investigation arm displaying a SARS-CoV-2 RT-PCR Ct count above 34 (>34 cycles) performed on a saliva sample collected at Day 6 of experiment |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
after full treatment completion |
|
E.5.2 | Secondary end point(s) |
1) Clinical evolution based on the daily filling of the FLU-PRO self-questionnaire, defined by daily comparison (up to and including Day 10 of experiment) of the distribution and mean of FLU-PRO score in each investigation arm, in points.
2) Rate, in percent, of subjects in each investigation arm displaying a negative viral culture (impossibility to cultivate SARS-CoV-2, see Section 7 for methodology) of a nasopharyngeal swab sample collected at Day 3 of experiment.
3) Median time, in days, of viral shedding in the subjects in each investigation arm ; time of viral shedding being defined as the number of days in experiment (starting Day 1) up to and not including the first Day of collection of a saliva sample which RT-PCR Ct count is above 34 (>34).
4) Evolution of the daily distribution and mean RT-PCR Ct count, in number of cycles, compared between the two investigation arms, performed on saliva samples collected daily in all the subjects, from Day 1 included to Day 6 included.
5) Rate, in percent, of subjects in each investigation arm having reported any kind of adverse events and reactions, either spontaneously or via prospective adverse event investigation (by daily phone calls of the Study Nurse), including specific comparison according to :
- the organic system they affect, be it encompassed by the table in Appendix 2 or not ;
- their quality and severity class : Adverse Event (AE), Severe Adverse Event (SAE), Suspected Unexpected Serious Adverse Reaction (SUSAR).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1)up to and including Day 10 of experiment
2)at Day 3 of experiment
3)from Day 1 to Day 6
4)from Day 1 to Day 6
5)from Day 1 to Day 10 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |